119 related articles for article (PubMed ID: 2522918)
1. Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.
Awwad HK; el Badawy S; abd el Baki H; Zaghloul M; el Moneim Osman A; Akoush H; Fairchild K
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1083-4. PubMed ID: 2522918
[TBL] [Abstract][Full Text] [Related]
2. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
[TBL] [Abstract][Full Text] [Related]
4. Kinetic uptake of etanidazole in lung carcinoma and normal tissue in vivo.
Busutti L; Breccia A; Ferri E; Falcone F; Bertoni F
Int J Radiat Oncol Biol Phys; 1992; 22(3):585-8. PubMed ID: 1531219
[TBL] [Abstract][Full Text] [Related]
5. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
Coleman CN; Noll L; Howes AE; Harris JR; Zakar J; Kramer RA
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1085-7. PubMed ID: 2522919
[TBL] [Abstract][Full Text] [Related]
6. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma.
Evans SM; LaCreta F; Helfand S; VanWinkle T; Curran WJ; Brown DQ; Hanks G
Int J Radiat Oncol Biol Phys; 1991 Apr; 20(4):703-8. PubMed ID: 1825993
[TBL] [Abstract][Full Text] [Related]
7. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Bleehen NM; Newman HF; Maughan TS; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
[TBL] [Abstract][Full Text] [Related]
8. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
Lee DJ; Phillips TL; Coleman CN; Cosmatos D; Davis LW; Wasserman TH; Marcial VA; Rubin P
Int J Radiat Oncol Biol Phys; 1992; 22(3):569-71. PubMed ID: 1531215
[TBL] [Abstract][Full Text] [Related]
9. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
[TBL] [Abstract][Full Text] [Related]
10. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: a possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination.
Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1011-4. PubMed ID: 2522916
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and subcellular localization of radiosensitizers.
Stratford MR
BJR Suppl; 1992; 24():100-4. PubMed ID: 1290683
[No Abstract] [Full Text] [Related]
12. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
[TBL] [Abstract][Full Text] [Related]
13. Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508.
Lespinasse F; Thomas C; Bonnay M; Malaise EP; Guichard M
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1105-9. PubMed ID: 2522920
[TBL] [Abstract][Full Text] [Related]
14. Uptake and additivity of the radiosensitizing effects of Ro 03-8799 and SR-2508 in mammalian cells in vitro.
Watts ME; Dennis MF; Woodcock M
Br J Radiol; 1987 Dec; 60(720):1233-5. PubMed ID: 2961396
[No Abstract] [Full Text] [Related]
15. Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man.
Workman P; Newman HF; Bleehen NM; Ward R; Smithen CE
Cancer Chemother Pharmacol; 1991; 28(2):118-22. PubMed ID: 2060082
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
17. Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas.
Hurwitz SJ; Coleman CN; Riese N; Loeffler JS; Alexander E; Buswell L; Neben TY; Shargel L; Kramer RA
Int J Radiat Oncol Biol Phys; 1992; 22(3):573-6. PubMed ID: 1531216
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
[TBL] [Abstract][Full Text] [Related]
19. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
Oya N; Shibamoto Y; Sasai K; Shibata T; Murata R; Takagi T; Iwai H; Suzuki T; Abe M
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):119-27. PubMed ID: 7642409
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
Taghian A; Lespinasse F; Guichard ME
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1535-40. PubMed ID: 1834621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
